Table 1.
Baseline characteristics and prior treatments (safety analysis set, N = 17)
| Value | ||
|---|---|---|
| Sex, n (%) | Male | 13 (76.5) |
| Female | 4 (23.5) | |
| Age, n (%) | Median (range) | 63.0 (29‐83) |
| <65 years | 9 (52.9) | |
| ≥65 years | 8 (47.1) | |
| Time since diagnosis, months | Median (range) | 24.0 (8.9‐89.0) |
| ECOG PS, n (%) | 0 | 8 (47.1) |
| 1 | 9 (52.9) | |
| Disease subtype, n (%) | Nodular sclerosis | 8 (47.1) |
| Lymphocyte rich | 0 (0.0) | |
| Mixed cellularity | 6 (35.3) | |
| Lymphocyte depleted | 2 (11.8) | |
| Unclassified | 1 (5.9) | |
| Disease stage at study enrolment, n (%) | II | 4 (23.5) |
| III | 5 (29.4) | |
| IV | 8 (47.1) | |
| B symptoms, n (%) | Absent | 12 (70.6) |
| Present | 5 (29.4) | |
| Relapse or refractory† (to most recent therapy), n (%) | Relapse | 1 (5.9) |
| Refractory | 16 (94.1) | |
| Number of prior chemotherapy regimens | Median (range) | 3 (2–5) |
| Prior brentuximab vedotin | 17 (100.0) | |
| BOR to brentuximab vedotin, n (%) | CR | 2 (11.8) |
| PR | 5 (29.4) | |
| SD | 4 (23.5) | |
| PD | 5 (29.4) | |
| Not evaluated | 1 (5.9) | |
| Prior ASCT, n (%) | 5 (29.4) | |
| BOR to ASCT, n (%) | CR | 3 (60.0) |
| PR | 1 (20.0) | |
| SD | 1 (20.0) | |
| Prior radiotherapy, n (%) | 9 (52.9) |
Data are presented as the n (%), unless otherwise indicated. ASCT, autologous stem cell transplantation; BOR, best overall response; CR, complete remission; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; PR, partial remission; SD, stable disease. †Relapse indicates best response of complete remission to the most recent prior therapy, and refractory indicates best response of partial remission, stable disease, or progressive disease to the most recent prior therapy.